Drug manufacturing and marketing companies are constantly monitored by regulatory bodies that have stringent rules on manufacturing processes, marketing messages and adverse events reporting. So, it is vital that drug companies keep the channels of communication open, when it comes to dealing with regulatory authorities.

There is a need to constantly update investigators on safety issues pertaining to the drug development cycle and the aftermath as well. This is a labor-intensive process that requires the use of a tremendous amount of resources as safety concerns need to be printed and processed before being handed over to investigators.

However, with the development of information technology, drug companies are these days choosing to employ automated safety-to-investigator technologies that save heavily on time and money. These automated technologies enable drug companies to automatically monitor, track, process and manage the distribution of clinical safety reports and relevant documentation to investigators, regulatory authorities, ethics committees and other stakeholders.

Investing in a fully automated safety-to-investigator system significantly reduces the time and the resources needed to collect, manage and distribute safety documents. It cuts back on costs and overheads which can be directed to the development of better drugs or other biological products.

Most of these pharmacovigilance systems that send out safety reports to investigators are developed from the investigator's perspective. Hence, the documents are easy-to-comprehend and up-to-date, at all times.

When it comes to Adverse Events Reporting, these automated systems are crucial to the smooth flow of information. The reports sent out help investigators keep track of any adverse effects of the drugs even after they hit the market. Also, in the case of signal detection, the system helps investigators and regulators keep tabs on the processes undertaken to rectify the adverse signals.